PneumoniaPNEUMIOTNCT07439146
Risk of Pneumonia in Intubated Patients in Emergency Situations
An observational study of Pneumonia and Orotracheal Intubation, run by University Hospital, Clermont-Ferrand at 6 sites in France.
Trial summary
Orotracheal intubation in emergency medicine is a vital procedure for ensuring adequate oxygenation and ventilation in patients with respiratory distress or in shock. However, this procedure exposes patients to complications such as pneumonia. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pneumonia, Orotracheal Intubation
- How many people
- 600 participants
- Where
- 6 sitesFrance
- Study dates
- 9 Feb 2026to 31 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Study population is patient intubated in emergency situation and patients intubated in non-emergency situation following to the admission of intensive care in 2024.
Who may be able to join
- Adult man or woman
- Emergency and non-emergency intubated patient in 2024
- Patient hospitalized in intensive care following intubation in 2024
Who cannot join
- Patient under guardianship, curatorship or safeguard of justice
- Pregnant woman
- Refusal to participate
Trial locations and contacts
6 sites in 1 country. Contact the study team or a site near you to ask about taking part.
6 sites in 1 country
France6 sites
CH Aurillac
Aurillac, 15000
Jonathan DUCHENNE, 0471468241, j.duchenne@ch-aurillac.fr
Jonathan DUCHENNE
CHU de Clermont-Ferrand, Clermont-Ferrand
Clermont-Ferrand
Lise LACLAUTRE, 334.73.754.963, promo_interne_drci@chu-clermontferrand.fr
Jean-Bpatiste BOUILLON-MINOIS
CH du Puy en Velay
Le Puy-en-Velay, 43000
Adrien ROBERT, No phone number, adrien.robert@ch-lepuy.fr
Adrien ROBERT
CH de Montluçon
Montluçon, 03100
Sébastien LOISEAU, 0470027210, s.loiseau@ch-montlucon.fr
Sébastien LOISEAU
CH de Moulins
Moulins, 03000
Fabien THOMAS, No phone number, f.thomas@ch-moulins-yzeure.fr
Fabien THOMAS
CH de Vichy
Vichy, 03200
Gaël GIBOT, No phone number, gael.gibot@ch-vichy.fr
Gaël GIBOT
About this study
Orotracheal intubation in emergency medicine is a vital procedure for ensuring adequate oxygenation and ventilation in patients with respiratory distress or in shock. However, this procedure exposes patients to complications such as pneumonia. In the matter of fact, the urgency of the procedure means that it is not possible to wait until the patient's stomach is empty. Pneumonia significantly increase patient morbidity and mortality. Therapeutic management must be early and appropriate to improve the patient's prognosis.
The aim of this study is to compare the rate of pneumonia occurring in patients intubated in emergency situations with that in patients intubated in non-emergency situations in all 2024. Health data will only collected from patient's medical records.
- Conditions
- Pneumonia, Orotracheal Intubation
- Keywords
- Orotracheal intubation in emergency, Pneumonia
- Medical subject headings
- Pneumonia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Intubated patients in emergency situations | Health data will be collected only with medical's record of intubated patients in emergency situation in 2024. | |
| Intubated patients in non emergency situations | Health data will be collected only with medical's record of intubated patients in non emergency situation in 2024. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pneumonia rate in 48 hours after the start of orotracheal intubation.
Rate of pneumonia occuring within 48 hours of the start of orotracheal intubation.
Measured: Hour 48
Secondary outcomes (9)
Pneumonia rate occuring 48 hours after the start of orotracheal intubation.
Rate of pneumonia occuring more than 48 hours after the start of orotracheal intubation.
Measured: 3 months
Duration of mechanical ventilation
Duration of mechanical ventilation
Measured: Up to the end of mechanical ventilation (assessed up to 1 month)
Duration of stay in intensive care
Duration of stay in intensive care
Measured: Up to intensive care discharge (assessed up to 1 month)
Duration of hospital stay
Duration of hospital stay
Measured: Up to hospital discharge (assessed up to 3 months)
Mortality rate
Mortality rate
Measured: Inclusion + 1 year
Type of bacteria responsible for pneumonia
The bacterial species responsible for pneumonia will be identified using biological samples (blood, urine, bronchial secretions) taken from patients in both groups. The identification of bacterial species will be carried out in the laboratory.
Measured: The day of the diagnosis of pneumonia (assessed up to 1 month)
Type of antibiotic administered for pneumonia
Type of antibiotic administered for pneumonia in each group
Measured: Up to the last day of antibiotic treatment (assessed up to 3 months)
Antibiotic doses administered for pneumonia
Comparison of antibiotic doses in g or mg administered in each group
Measured: Up to the last day of antibiotic treatment (assessed up to 3 months)
Duration of antibiotic treament for pneumonia
Duration of antibiotic treament for pneumonia in each group
Measured: Up to the last day of antibiotic treatment (assessed up to 3 months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Feb 2026
- Study start9 Feb 2026 (estimated)
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PneumoniaStudies of the same condition, open and under way.
- More trials run by University Hospital, Clermont-FerrandThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 600 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Clermont-Ferrand
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jean-Baptiste BOUILLON-MINOIS, Principal investigator, University Hospital, Clermont-Ferrand
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07439146
- Sponsor's protocol ID
- 2025_BOUILLON MINOIS_Pneumiot
- Acronym
- PNEUMIOT
- Status last verified
- Jan 2026
- First submitted
- 6 Feb 2026
- Last updated
- 27 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Risk of Pneumonia in Intubated Patients in Emergency Situations
- ClinicalTrials.gov ID
- NCT07439146
- Acronym / sponsor ID
- PNEUMIOT / 2025_BOUILLON MINOIS_Pneumiot
- Conditions
- Pneumonia, Orotracheal Intubation
- Keywords
- Orotracheal intubation in emergency, Pneumonia
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 600 participants (estimated)
- Lead sponsor
- University Hospital, Clermont-FerrandUniversity, hospital or other
- Study start
- 9 Feb 2026 (estimated)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 27 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Orotracheal intubation in emergency medicine is a vital procedure for ensuring adequate oxygenation and ventilation in patients with respiratory distress or in shock. However, this procedure exposes patients to complications such as pneumonia. In the matter of fact, the urgency of the procedure means that it is not possible to wait until the patient's stomach is empty. Pneumonia significantly increase patient morbidity and mortality. Therapeutic management must be early and appropriate to improve the patient's prognosis.
The aim of this study is to compare the rate of pneumonia occurring in patients intubated in emergency situations with that in patients intubated in non-emergency situations in all 2024. Health data will only collected from patient's medical records.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intubated patients in emergency situations | – | –Health data will be collected only with medical's record of intubated patients in emergency situation in 2024. |
| Intubated patients in non emergency situations | – | –Health data will be collected only with medical's record of intubated patients in non emergency situation in 2024. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Study population is patient intubated in emergency situation and patients intubated in non-emergency situation following to the admission of intensive care in 2024.
Key inclusion criteria (3 listed)
- Adult man or woman
- Emergency and non-emergency intubated patient in 2024
- Patient hospitalized in intensive care following intubation in 2024
Key exclusion criteria (3 listed)
- Patient under guardianship, curatorship or safeguard of justice
- Pregnant woman
- Refusal to participate
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Pneumonia rate in 48 hours after the start of orotracheal intubation.
Time frame: Hour 48
Rate of pneumonia occuring within 48 hours of the start of orotracheal intubation.
9 secondary outcomes
Pneumonia rate occuring 48 hours after the start of orotracheal intubation.
Time frame: 3 months
Duration of mechanical ventilation
Time frame: Up to the end of mechanical ventilation (assessed up to 1 month)
Duration of stay in intensive care
Time frame: Up to intensive care discharge (assessed up to 1 month)
Duration of hospital stay
Time frame: Up to hospital discharge (assessed up to 3 months)
Mortality rate
Time frame: Inclusion + 1 year
Type of bacteria responsible for pneumonia
Time frame: The day of the diagnosis of pneumonia (assessed up to 1 month)
Type of antibiotic administered for pneumonia
Time frame: Up to the last day of antibiotic treatment (assessed up to 3 months)
Antibiotic doses administered for pneumonia
Time frame: Up to the last day of antibiotic treatment (assessed up to 3 months)
Duration of antibiotic treament for pneumonia
Time frame: Up to the last day of antibiotic treatment (assessed up to 3 months)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Pneumonia
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
Not yet recruiting
Expanded Diagnostic Strategy in Older Adults Hospitalized With Community-Acquired Acute Respiratory Infection
Acute Respiratory Infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jean-Baptiste BOUILLON-MINOIS principal investigator
University Hospital, Clermont-Ferrand
6 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pneumonia and Orotracheal Intubation, run by University Hospital, Clermont-Ferrand at 6 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 27 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lise Laclautre (334.73.754.963, promo_interne_drci@chu-clermontferrand.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pneumonia rate in 48 hours after the start of orotracheal intubation. (time frame: Hour 48). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Feb 2026.